Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
SPRY
Stock Latest News
Ratings
ARS Pharmaceuticals: Buy Rating Reaffirmed on Improved Competitive Outlook After Aquestive’s Anaphylm Setback
3d ago
SPRY
Premium
Ratings
Regulatory Setbacks for Anaphylm Enhance ARS Pharmaceuticals’ Competitive Position and Support SPRY Buy Rating
3d ago
SPRY
Premium
The Fly
ARS Pharmaceuticals competitor gets FDA deficiency letter, says Raymond James
3d ago
AQST
SPRY
Premium
The Fly
ARS Pharmaceuticals announces NMPA approval for neffy 2 mg
14d ago
SPRY
Premium
Ratings
ARS Pharmaceuticals: Strategic Positioning and Market Potential for Neffy Justifies Buy Rating
2M ago
SPRY
Premium
The Fly
ARS Pharmaceuticals management to meet with Oppenheimer
2M ago
SPRY
Premium
The Fly
ARS Pharmaceuticals price target lowered to $35 from $40 at Oppenheimer
2M ago
SPRY
Premium
Company Announcements
ARS Pharmaceuticals Reports Strong Q3 2025 Growth
2M ago
SPRY
Premium
Company Announcements
Ars Pharmaceuticals’ Earnings Call Highlights Growth and Challenges
2M ago
SPRY
Premium
Ratings
Promising Outlook for ARS Pharmaceuticals: Buy Rating Affirmed by Lachlan Hanbury Brown
2M ago
SPRY
Premium
Company Announcements
ARS Pharmaceuticals Reports Q3 2025 Financial Results
2M ago
8K
SPRY
Premium
The Fly
ARS Pharmaceuticals reports Q3 EPS (52c), consensus (49c)
2M ago
SPRY
Premium
Pre-Earnings
SPRY Earnings this Week: How Will it Perform?
2M ago
SPRY
Premium
The Fly
DraftKings, Flutter downgraded: Wall Street’s top analyst calls
2M ago
CV
WM
Premium
The Fly
ARS Pharmaceuticals launches ‘Get neffy on Us’
2M ago
SPRY
Premium
The Fly
ARS Pharmaceuticals resumed with a Buy at Roth Capital
2M ago
SPRY
Premium
Company Announcements
Ars Pharmaceuticals’ Latest Study: A Potential Game-Changer in Allergy Treatment
3M ago
SPRY
Premium
Company Announcements
Ars Pharmaceuticals’ Promising Study on ARS-2 for Chronic Urticaria: What Investors Need to Know
3M ago
SPRY
Premium
The Fly
ARS Pharmaceuticals receives favorable decision from EPO on neffy
3M ago
SPRY
Premium
Ratings
ARS Pharmaceuticals: Strategic Financial Maneuvers and Market Potential Drive Buy Rating
3M ago
SPRY
Premium
Company Announcements
ARS Pharmaceuticals Secures $250 Million Credit Agreement
3M ago
8K
SPRY
Premium
Ratings
ARS Pharmaceuticals Gains Momentum: Buy Rating Justified by Market Share and Script Volume Increase
4M ago
SPRY
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
